Targeting aggressive cancer stem cells in glioblastoma

Frontiers in Oncology

Volumn 5, Issue JUL, 2015, Pages

  Seymour, Tracy ^a,b   Nowak, Anna ^a   Kakulas, Foteini ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Glioblastoma; Glioma stem cells; Gliosarcoma; Nanog homeobox; Octamer binding transcription factor 4; Pluripotency genes; SRY (sex determining region Y) box 2

Indexed keywords

BEVACIZUMAB; CD24 ANTIGEN; HERMES ANTIGEN; IRINOTECAN; OCTAMER TRANSCRIPTION FACTOR 4; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TEMOZOLOMIDE; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; VASCULOTROPIN;

BRAIN TUMOR; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STEM CELL; CANCER SURGERY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CFU COUNTING; GENE AMPLIFICATION; GENE MUTATION; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; LEUKEMIA; OVARY CANCER; PATIENT CARE; PLURIPOTENT STEM CELL; POSTOPERATIVE CARE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT FAILURE; TUMOR GROWTH;

EID: 84940107521     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00159     Document Type: Review

References (80)

1. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol (2014) 16(Suppl 4):iv1-63. doi: 10.1093/neuonc/nou223.
2. Lutterbach J, Guttenberger R, Pagenstecher A. Gliosarcoma: a clinical study. Radiother Oncol (2001) 61:57-64. doi:10.1016/S0167-8140(01)00415-7.
3. de Carvalho AC, Nelson K, Lemke N, Lehman NL, Arbab AS, Kalkanis S. Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo. Stem Cells (2010) 28:181-90. doi:10.1002/stem.264.
4. Damodaran O, van Heerden J, Nowak AK, Bynevelt M, McDonald K, Marsh J. Clinical management and survival outcomes of gliosarcomas in the era of multimodality therapy. J Clin Neurosci (2014) 21:478-81. doi:10.1016/j.jocn.2013.07.042.
5. Albert FK, Forsting M, Sartor K, Adams HP, Kunze S. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery (1994) 34:45-60. doi:10.1097/00006123-199401000-00008.
6. Dobes M, Khurana VG, Shadbolt B, Jain S, Smith SF, Smee R. Increasing incidence of glioblastoma multiforme and meningioma, and decreasing incidence of Schwannoma (2000-2008): findings of a multicenter Australian study. Surg Neurol Int (2011) 2:176. doi:10.4103/2152-7806.90696.
7. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 352:987-96. doi:10.1056/NEJMoa043330.
8. Andaloussi-Saghir K, Oukabli M, El Marjany M, Sifat H, Hadadi K, Mansouri H. Secondary gliosarcoma after the treatment of primary glioblastoma multiforme. N Am J Med Sci (2011) 3:527-30. doi:10.4297/najms.2011.3527.
9. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 10:459-66. doi:10.1016/S1470-2045(09)70025-7.
10. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J. Identification of a cancer stem cell in human brain tumors. Cancer Res (2003) 63:5821-8.
11. Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene (2004) 23:9392-400. doi:10.1038/sj.onc.1208311.
12. Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J, Klein B. Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun (2009) 383:157-62. doi:10.1016/j.bbrc.2009.02.156.
13. Guo Y, Liu S, Wang P, Zhao S, Wang F, Bing L. Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas. Histopathology (2011) 59:763-75. doi:10.1111/j.1365-2559.2011.03993.x.
14. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 17:98-110. doi:10.1016/j.ccr.2009.12.020.
15. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 9:157-73. doi:10.1016/j.ccr.2006.02.019.
16. Vitucci M, Hayes DN, Miller CR. Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. Br J Cancer (2011) 104:545-53. doi:10.1038/sj.bjc.6606031.
17. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 114:97-109. doi:10.1007/s00401-007-0278-6.
18. Reis RM, Konu-Lebleblicioglu D, Lopes JM, Kleihues P, Ohgaki H. Genetic profile of gliosarcomas. Am J Pathol (2000) 156:425-32. doi:10.1016/S0002-9440(10)64746-3.
19. Jackson M, Hassiotou F, Nowak A. Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target. Carcinogenesis (2015) 36:177-85. doi:10.1093/carcin/bgu243.
20. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med (1980) 303:1323-9. doi:10.1056/NEJM198012043032303.
21. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 352:997-1003. doi:10.1056/NEJMoa043331.
22. Wesolowski JR, Rajdev P, Mukherji SK. Temozolomide (Temodar). AJNR Am J Neuroradiol (2010) 31:1383-4. doi:10.3174/ajnr.A2170.
23. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer (2004) 4:296-307. doi:10.1038/nrc1319.
24. Soejima H, Zhao W, Mukai T. Epigenetic silencing of the MGMT gene in cancer. Biochem Cell Biol (2005) 83:429-37. doi:10.1139/o05-140.
25. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med (2003) 9:669-76. doi:10.1038/nm0603-669.
26. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 27:4733-40. doi:10.1200/JCO.2008.19.8721.
27. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol (2009) 27:740-5. doi:10.1200/JCO.2008.16.3055.
28. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med (2014) 370:709-22. doi:10.1056/NEJMoa1308345.
29. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 370:699-708. doi:10.1056/NEJMoa1308573.
30. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res (2006) 66:9339-44. doi:10.1158/0008-5472.CAN-06-3126.
31. Campbell LL, Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle (2007) 6:2332-8. doi:10.4161/cc.6.19.4914.
32. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell (2010) 17:362-75. doi:10.1016/j.ccr.2009.12.049.
33. Li L, Bhatia R. Stem cell quiescence. Clin Cancer Res (2011) 17:4936-41. doi:10.1158/1078-0432.CCR-10-1499.
34. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature (2001) 414:105-11. doi:10.1038/35102167.
35. Azari H, Millette S, Ansari S, Rahman M, Deleyrolle LP, Reynolds BA. Isolation and expansion of human glioblastoma multiforme tumor cells using the neurosphere assay. J Vis Exp (2011) 56:e3633. doi:10.3791/3633.
36. Passegue E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci U S A (2003) 100(Suppl 1):11842-9. doi:10.1073/pnas.2034201100.
37. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 100:3983-8. doi:10.1073/pnas.0530291100.
38. Ma L, Lai D, Liu T, Cheng W, Guo L. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. Acta Biochim Biophys Sin (Shanghai) (2010) 42:593-602. doi:10.1093/abbs/gmq067.
39. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 9:391-403. doi:10.1016/j.ccr.2006.03.030.
40. Brescia P, Ortensi B, Fornasari L, Levi D, Broggi G, Pelicci G. CD133 is essential for glioblastoma stem cell maintenance. Stem Cells (2013) 31:857-69. doi:10.1002/stem.1317.
41. Zarkoob H, Taube JH, Singh SK, Mani SA, Kohandel M. Investigating the link between molecular subtypes of glioblastoma, epithelial-mesenchymal transition, and CD133 cell surface protein. PLoS One (2013) 8:e64169. doi:10.1371/journal.pone.0064169.
42. Nakano I. Stem cell signature in glioblastoma: therapeutic development for a moving target. J Neurosurg (2015) 122:324-30. doi:10.3171/2014.9.JNS132253.
43. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res (2007) 67:4010-5. doi:10.1158/0008-5472.CAN-06-4180.
44. Campos B, Gal Z, Baader A, Schneider T, Sliwinski C, Gassel K. Aberrant self-renewal and quiescence contribute to the aggressiveness of glioblastoma. J Pathol (2014) 234:23-33. doi:10.1002/path.4366.
45. Shen Q, Wang Y, Kokovay E, Lin G, Chuang SM, Goderie SK. Adult SVZ stem cells lie in a vascular niche: a quantitative analysis of niche cell-cell interactions. Cell Stem Cell (2008) 3:289-300. doi:10.1016/j.stem.2008.07.026.
46. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B. A perivascular niche for brain tumor stem cells. Cancer Cell (2007) 11:69-82. doi:10.1016/j.ccr.2006.11.020.
47. Charles N, Ozawa T, Squatrito M, Bleau AM, Brennan CW, Hambardzumyan D. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell (2010) 6:141-52. doi:10.1016/j.stem.2010.01.001.
48. Hovinga KE, Shimizu F, Wang R, Panagiotakos G, Van Der Heijden M, Moayedpardazi H. Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells (2010) 28:1019-29. doi:10.1002/stem.429.
49. Moore N, Lyle S. Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance. J Oncol (2011) 2011:1-11. doi:10.1155/2011/396076.
50. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature (2012) 488:522-6. doi:10.1038/nature11287.
51. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 444:756-60. doi:10.1038/nature05236.
52. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR. Notch promotes radioresistance of glioma stem cells. Stem Cells (2010) 28:17-28. doi:10.1002/stem.261.
53. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer (2006) 5:67. doi:10.1186/1476-4598-5-67.
54. Diehn M, Cho RW, Clarke MF. Therapeutic implications of the cancer stem cell hypothesis. Semin Radiat Oncol (2009) 19:78-86. doi:10.1016/j.semradonc.2008.11.002.
55. Ables JL, Breunig JJ, Eisch AJ, Rakic P. Not(ch) just development: notch signalling in the adult brain. Nat Rev Neurosci (2011) 12:269-83. doi:10.1038/nrn3024.
56. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells (2010) 28:5-16. doi:10.1002/stem.254.
57. Cao Y, Lathia JD, Eyler CE, Wu Q, Li Z, Wang H. Erythropoietin receptor signaling through STAT3 is required for glioma stem cell maintenance. Genes Cancer (2010) 1:50-61. doi:10.1177/1947601909356352.
58. Levy DE, Lee CK. What does Stat3 do? J Clin Invest (2002) 109:1143-8. doi:10.1172/JCI0215650.
59. Haapa-Paananen S, Chen P, Hellström K, Kohonen P, Hautaniemi S, Kallioniemi O. Functional profiling of precursor microRNAs identifies microRNAs essential for glioma proliferation. PLoS One (2013) 8:e60930. doi:10.1371/journal.pone.0060930.
60. Shi L, Wang Z, Sun G, Wan Y, Guo J, Fu X. miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2. Neuromolecular Med (2014) 16:517-28. doi:10.1007/s12017-014-8305-y.
61. Bleau AM, Huse JT, Holland EC. The ABCG2 resistance network of glioblastoma. Cell Cycle (2009) 8:2936-44. doi:10.4161/cc.8.18.9504.
62. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell (2005) 122:947-56. doi:10.1016/j.cell.2005.08.020.
63. Hassiotou F, Beltran A, Chetwynd E, Stuebe AM, Twigger AJ, Metzger P. Breastmilk is a novel source of stem cells with multilineage differentiation potential. Stem Cells (2012) 30:2164-74. doi:10.1002/stem.1188.
64. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells (2009) 27:40-8. doi:10.1634/stemcells.2008-0493.
65. Schmitz M, Temme A, Senner V, Ebner R, Schwind S, Stevanovic S. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer (2007) 96:1293-301. doi:10.1038/sj.bjc.6603802.
66. Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature (2014) 511:246-50. doi:10.1038/nature13305.
67. Pesce M, Scholer HR. Oct-4: gatekeeper in the beginnings of mammalian development. Stem Cells (2001) 19:271-8. doi:10.1634/stemcells.19-4-271.
68. Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet (2006) 38:431-40. doi:10.1038/ng1760.
69. Thiel G. How Sox2 maintains neural stem cell identity. Biochem J (2013) 450:e1-2. doi:10.1042/BJ20130176.
70. Sherwood RI, Chen TY, Melton DA. Transcriptional dynamics of endodermal organ formation. Dev Dyn (2009) 238:29-42. doi:10.1002/dvdy.21810.
71. Favaro R, Appolloni I, Pellegatta S, Sanga AB, Pagella P, Gambini E. Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma. Cancer Res (2014) 74:1833-44. doi:10.1158/0008-5472.CAN-13-1942.
72. Du Z, Jia D, Liu S, Wang F, Li G, Zhang Y. Oct4 is expressed in human gliomas and promotes colony formation in glioma cells. Glia (2009) 57:724-33. doi:10.1002/glia.20800.
73. Niu CS, Li DX, Liu YH, Fu XM, Tang SF, Li J. Expression of NANOG in human gliomas and its relationship with undifferentiated glioma cells. Oncol Rep (2011) 26:593-601. doi:10.3892/or.2011.1308.
74. Jun HJ, Bronson RT, Charest A. Inhibition of EGFR induces a c-MET-driven stem cell population in glioblastoma. Stem Cells (2014) 32:338-48. doi:10.1002/stem.1554.
75. Ye F, Li Y, Hu Y, Zhou C, Hu Y, Chen H. Expression of Sox2 in human ovarian epithelial carcinoma. J Cancer Res Clin Oncol (2011) 137:131-7. doi:10.1007/s00432-010-0867-y.
76. Bareiss PM, Paczulla A, Wang H, Schairer R, Wiehr S, Kohlhofer U. SOX2 expression associates with stem cell state in human ovarian carcinoma. Cancer Res (2013) 73:5544-55. doi:10.1158/0008-5472.CAN-12-4177.
77. Stolzenburg S, Rots MG, Beltran AS, Rivenbark AG, Yuan X, Qian H. Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res (2012) 40:6725-40. doi:10.1093/nar/gks360.
78. Peng S, Maihle NJ, Huang Y. Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene (2010) 29:2153-9. doi:10.1038/onc.2009.500.
79. Siu MK, Wong ES, Kong DS, Chan HY, Jiang L, Wong OG. Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers. Oncogene (2013) 32:3500-9. doi:10.1038/onc.2012.363.
80. Beltran AS, Graves LM, Blancafort P. Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function. Oncogene (2014) 33:4767-77. doi:10.1038/onc.2013.422.